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In a recent human PET study Svensson et al. addressed again the subject of the possibility to measure extrastriatal D2/3 receptor densities with the PET tracer [11C]raclopride. Healthy subjects were measured at baseline and after dosing with two different amounts of quietiapine, which -among other binding properties -is an antagonist for D2 receptors. As a measure for the available receptor density, the nondisplaceable binding potential (BPnd) was calculated from [11C]raclopride PET data by application of the simplified reference tissue model (SRTM) using the cerebellum as reference region. Under the assumption that the level of endogenous dopamine remains unchanged by the drug, the application of quietiapine should theoretically reduce BPnd by the same fraction in every brain region (if BPnd reflects specific binding of the tracer to D2 receptors).
Accordingly quietiapine reduced BPnd in the putamen, caudate, and nucleus accumbens in a dose-dependent manner. BPnd in the thalamus and the temporal cortex was also significantly reduced in a dose-dependent manner but to a lower extent as compared to the basal ganglia. In other cortical regions however no clear reduction of BPnd could be observed. The authors conclude that using the SRTM with the cerebellum as reference region [11C]raclopride PET is not suitable to measure D2/3 receptors in extrastriatal regions.
While the overall conclusion of the study is well supported by data, we want to point out that this does not mean that [11C]raclopride PET is per se not suitable for the assessment of extrastriatal dopamine receptors. We want to draw attention to an important methodological aspect that warrants further discussion: the role of the cerebellum as reference region.
In rodents, dopamine transporters as well as dopamine receptors in the cerebellum have been established in various studies (Boyson et al., 1986; Camps et al., 1990; Diaz et al., 1995) . Dopamine receptors (including D2R and D3R) have also been identified in the human cerebellum (Herroelen et al., 1994; Hurley et al., 2003; Khan et al., 1998) . It is therefore questionable if the assumption of the cerebellum as a receptor-free region is strictly valid and if the cerebellum is qualified for its role as reference region to analyze [11C]raclopride PET data in regions with low dopamine receptor density.
One of the pioneering studies by the developers of [11C]raclopride at the Karolinska Institute already indicated potential specific binding of [11C]raclopride in the cerebellum (Farde et al., 1988) . In this study the researchers compared accumulation of the [11C]raclopride with its pharmacologically inactive enantiomer [11C]FLB472 in the brain of healthy volunteers. [11C]FLB472 has identical chemical properties as [11C]raclopride with the only difference that it does not bind to dopamine receptors. Results of this study show that the distribution volume of [11C]raclopride in the cerebellum was in the order of 10% higher than the distribution volume of [11C]FLB472. The difference of distribution volumes in the cortex was at about the same order of magnitude.
While relatively low specific binding in the cerebellum as reference region has negligible effects on the quantification of regions with high specific binding using a reference tissue model, it has -even at low amounts -essential consequences for the analysis of regions with low specific binding, in receptor-blocking studies in particular. In the theoretical example illustrated in Figure 1 , we assume that a drug was given that reduces the amount of specific binding by 50%. Evaluating these data in terms of the reference tissue model would show a reduction of BPnd in the putamen by 40% and in the thalamus by 14% but in the cortex it would not show any reduction at all. Accordingly, in receptor-blocking studies the reference tissue model works well for regions with much higher specific binding than in the reference region but fails for analyzing regions with specific binding at the order of magnitude of the binding in the reference region.
Interestingly, the data of Svensson et al. indeed show a reduction of [11C]raclopride accumulation in the cerebellum by ~10% after application of quietiapine. Moreover, their data show a reduction of blocking efficiency in the thalamus and the temporal cortex compared to the putamen and no blocking in other cortical regions.
In summary, the data of Svensson et al. clearly demonstrate that the cerebellum is not a suitable reference region for the analysis of extrastriatal [11C]raclopride data in receptor-blocking studies. However, their results do not support the conclusion that there is no detectable specific binding of [11C]raclopride outside of the striatum and that published studies on extrastriatal [11C]raclopride binding are based on artifacts Thanarajah et al., 2019) . Recent studies have not only demonstrated good test-retest reliability in [11C]raclopride binding but also showed good correlations with binding of the high-affinity tracer [18F]fallypride in intra-and extrastriatal regions of the human brain (Alakurtti et al., 2015; Karalija et al., 2019; Papenberg et al., 2019) . This indicates that specific extrastriatal [11C]raclopride binding appears to be low but detectable.
Figure 1:
Distribution volumes (V d ) of specific (sp) and non-displaceable (nd) binding in the cerebellum (Cb), the cortex (Ctx), the thalamus (Tha), and the putamen (Put) at baseline and after application of a drug that reduces specific binding by 50%. The lower panel shows the resulting BPnd values calculated using the cerebellum as reference region.
